Get the Stockscreener App
194.19
0.08%
-0.16
After Hours:
194.19
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $194.19, with a volume of 2.84M.
It is down -0.08% in the last 24 hours and down -0.21% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$194.35
Open:
$195
24h Volume:
2.84M
Relative Volume:
0.65
Market Cap:
$343.01B
Revenue:
$55.00B
Net Income/Loss:
$5.34B
P/E Ratio:
53.20
EPS:
3.65
Net Cash Flow:
$17.78B
1W Performance:
-0.05%
1M Performance:
-0.21%
6M Performance:
+15.92%
1Y Performance:
+30.03%
1-Day Range:
$193.58
$195.24
1-Week Range:
$191.95
$195.24
52-Week Range:
$135.85
$199.95
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Simplicity Wealth LLC Reduces Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors. - The Motley Fool
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie (NYSE:ABBV) Trading Up 0.1% on Analyst Upgrade - MarketBeat
Ex-Dividend Reminder: Hormel Foods, Abbott Laboratories and AbbVie - Nasdaq
Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and more - Seeking Alpha
CCM Investment Advisers LLC Sells 6,991 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential - MarketBeat
Is AbbVie Inc. (NYSE:ABBV) The Most Popular Stock Among Mutual Funds According To Goldman Sachs? - Yahoo Finance
AbbVie (ABBV) Stock Moves -0.21%: What You Should Know - Yahoo Finance
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AbbVie (NYSE:ABBV) Shares Down 0.3%What's Next? - MarketBeat
AbbVie Shares Rebound After Six-day Slump Despite Ongoing Challe - GuruFocus.com
AbbVie Shares Rebound After Six-day Slump Despite Ongoing Challenges - Yahoo Finance
Autoimmune Hepatitis Market to Rise, 2032 | AbbVie Inc., Gilead - openPR
Design Firm Helps Drugmaker Improve Ergonomics of Injector Pen - Assembly Magazine
AbbVie (NYSE:ABBV) Given New $215.00 Price Target at Truist Financial - MarketBeat
Abbvie pulls 2 hepatitis treatments from EU market - Liver Disease News
Tobam Lowers Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Geriatric Medicine Industry Assessment 2024-2030, Featuring - GlobeNewswire
AbbVie 2024: What’s next - PharmaLive
GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News
UBS Group Increases AbbVie (NYSE:ABBV) Price Target to $195.00 - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie snaps six days of losses, trades in the green - Seeking Alpha
Tia Mowry gets real about eczema at AbbVie’s NYC pop-up - MM+M Online
AbbVie (NYSE:ABBV) Shares Down 0.2%What's Next? - MarketBeat
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Shares Purchased by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors - MarketBeat
Germany Pharmaceuticals Market Report 2024-2028: Consolidation through Mergers and Acquisitions Catalyzing Growth - GlobeNewswire Inc.
AbbVie Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
AbbVie (NYSE:ABBV) Stock Price Down 0.5%Time to Sell? - MarketBeat
Legacy Private Trust Co. Grows Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's Top Brass Escape Suit Over Rinvoq Claims, For Now - Law360
AbbVie (NYSE:ABBV) Trading 0.4% Higher After Analyst Upgrade - MarketBeat
AbbVie (NYSE:ABBV) Price Target Raised to $212.00 at Barclays - MarketBeat
AbbVie Investors’ Suit Over Rinvoq Marketing Risks Dismissed - Bloomberg Law
AbbVie Inc. (NYSE:ABBV) is Oak Asset Management LLC's 7th Largest Position - MarketBeat
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades' - MSN
Breast tumors may mimic neurons to invade the brain - Drug Discovery News
3 Magnificent Dividend Stocks to Buy in October - The Motley Fool
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You? - The Motley Fool
Handelsbanken Fonder AB Has $226.30 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now - The Motley Fool
Ausdal Financial Partners Inc. Sells 456 Shares of AbbVie Inc. (NYSE:ABBV) - Defense World
EU withdraws marketing authorisation for Abbvie's hepatitis C drug - AOL
AbbVie (NYSE:ABBV) Trading Down 0.7%Should You Sell? - MarketBeat
AbbVie trims full-year earnings guidance due to R&D milestone costs - PharmaLive
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs - Yahoo Finance
Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM - AbbVie
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):